Showing 4421-4430 of 5327 results for "".
- FDA Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanomahttps://practicaldermatology.com/news/fda-expands-approval-of-yervoy-to-include-pediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma/2458113/The FDA has expanded the indication for Bristol-Myers Squibb's Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Yervoy was evaluated in two trials of pediatric patients:
- LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of-plaque-psoriasis/2458114/The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 recep
- DermTech Secures Billing Codes for its Proprietary Melanoma Testhttps://practicaldermatology.com/news/dermtech-secures-billing-codes-for-its-proprietary-melanoma-test/2458115/The American Medical Association (AMA) has granted DermTech, Inc. Category 1, Tier 2 Molecular Pathology procedure codes related to its proprietary test for the detection of melanoma related gene expression. The company has secured this Common Procedural Terminology (CPT) coding for LINC and PRAM
- Valeant to Sell Obagi Medical Products Business for $190 Mhttps://practicaldermatology.com/news/valeant-to-sell-obagi-medical-products-business-for-190-m/2458117/Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic ma
- Galderma CareConnect Patient Savings Card Program Passes Milestonehttps://practicaldermatology.com/news/galderma-careconnect-patient-savings-card-program-passes-milestone/2458119/The Galderma CareConnect patient savings program has surpassed the mark of 1,000,000 prescriptions filled through its patient access program. Committed to keeping accessibility remarkably simple and saving patients’ money, the company says the program is structured to work at any accredited
- Patent Challenge Filed for Generic Version Of Soolantra Creamhttps://practicaldermatology.com/news/patent-challenge-filed-for-generic-version-of-soolantra-cream/2458120/Perrigo Company plc's subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the FDA for a generic version of Soolantra® (ivermectin) cream, 1%. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a
- Tomatoes May Slash Skin Cancer Riskhttps://practicaldermatology.com/news/tomatoes-may-slash-skin-cancer-risk/2458122/Daily tomato consumption may cut skin cancer risk in half, according to a new study in mice. The Ohio State University researchers report their findings online in the journal
- FDA Approves Janssen's Tremfya for Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-for-moderate-to-severe-plaque-psoriasis/2458123/The FDA has approved Janssen's Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a
- Allergan CEO: Consensus Needed on Medical Aesthetic Treatment in Minorshttps://practicaldermatology.com/news/allergan-ceo-consensus-needed-on-medical-aesthetic-treatment-in-minors/2458125/Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still matu
- Foamix Pharmaceuticals Appoints David Domzalski as CEOhttps://practicaldermatology.com/news/foamix-pharmaceuticals-appoints-david-domzalski-as-ceo/2458137/Foamix Pharmaceuticals Ltd.'s Board of Directors has named David Domzalski Chief Executive Officer of the company effective immediately. Mr. Domzalski currently serves as President of Foamix's US subsidiary. He succeeds Dr. Dov